FDA Accepts Supplemental NDA for JYLAMVO by SHORLA
The FDA has accepted a supplemental NDA for JYLAMVO, which contains methotrexate as an active ingredient.
Asset / Drug
Drug and asset intelligence for SHORLA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Chemotherapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.